Table S4. NS3 T cell epitopes found in the literature. A) T helper epitopes
|
|
|
- Darleen Underwood
- 8 years ago
- Views:
Transcription
1 Table S4. NS3 T cell epitopes found in the literature A) T helper epitopes Epitope Protein Position Genotype MHC II Association Reference TRTIASPKGPVIQMY NS A class II (4) DLVGWPAPQGSRSLT NS A class II (4) CPAGHAVGIFRAAVCTRGVA NS A QGYKVLVLNPSVAAT NS A DRB1*0101, DRB1*0401, DRB1*1501,DRB1*0404 (23) DRB1*0101, DRB1*0401, DRB1*1001,DRB1*1104 (23) GGRHLIFCHSKKKCD NS B DR13,DR15 (9) LIFCHSKKKCDELAA NS A DRB1*15 (4) HSKKKCDEL NS A/1B DRB1*15 (4) TQTVDFSLDPTFTIE NS B DR13,DR15 (9) EQYVDFSLDPTFSIE NS A class II (16) MFDSSVLCECYDAGC NS A/1B DR7, DR13 (9) TTVRLRAYMNTPGLPV NS B DRB1*0701 (23) FPYLVAYQATVCARA NS B DR13,DR15 (9) TAYQATVCARAQAPP NS A class II (16) YLVAYQATVCARAQAP NS B DRB1*1001 (23)
2 B) CTL epitopes Epitope Protein Position Genotype MHC I Association Reference AYSQQTRGL NS B A24 (3) VEGEVQIVSTAAQTF NS A class I (4) CINGVWCTV NS A A2 (5) QTFLATCINGVCWTV NS A class I (4) ATCINGVCWTVYHGAGTRTI NS A class I (6) TRTIASPKGPVIQMY NS A class I (4) AGTRTIASPKGPVIQM NS A class I (7) MYTNVDQDL NS A A24 (8) RRRGDSRGSLLSPRP NS B class I (9) LLCPAGHAV NS A A2 (10) CPAGHAVGIFRAAVCTRGVA NS A A2 (6) HAVGLFRAA NS A A68 (6) AYAAQGYKVL NS B Cw*0303, Cw*0304 (11) TLGFGAYMSK NS A A11 (12) GAYMSKAHGV NS A/1B A11 (13) LGFGAYMSK NS A A3 (10) TITTGAPVTYSTYGK NS B A2 (14) TGAPVTYSTY NS B A2 (14) TGSPITYSTY NS A A2 (10) TYSTYGKFL NS A/1B A*2402 (15) CHAQDATTVL NS A B38 (16) HPNIEEVAL NS A/1B B*3501 (7) GEIPFYGKAI NS A B44 (17) GEIPFYGKAI NS A C*1402 (7) FYGKAIPIEAI NS B A*2402 (11) HSKKKCDEL NS A/1B B8 (4) HSKRKCDEL NS A/1B class I (7) HSKKKCDELT NS A B8 (18) ELAAKLVAL NS A B8 (19) ELAAKLVGL NS A B8 (20) LAAKLVALGINAVAY NS A A2 (6) ATDALMTCY NS A A1 (21) DVVVVATDALMTGYT NS A class I (4) GDVVVVSTDALMTGY NS A class I (7) ALMTGYTGDFDSVI NS A class I (7) STDALMTGFTGDFDS NS A class I (22) GFTGDFDSV NS A/1B A*0206 (11) CLIRLKPTLHGPTPLLYR NS A/1B class I (6) LIRLKPTL NS A/1B B8 (6) TLTHPVTK NS A A11 (12) EVTLTHPITKYIMTCMSA NS A/1B B8 (18) TLTHPITK NS A/1B A11 (18)
3 Supplementary references 1. Yamada, N., K. Tanihara, M. Mizokami, K. Ohba, A. Takada, M. Tsutsumi, and T. Date Full-length sequence of the genome of hepatitis C virus type 3a: comparative study with different genotypes. J Gen Virol 75 ( Pt 11): Kolykhalov, A.A., E.V. Agapov, K.J. Blight, K. Mihalik, S.M. Feinstone, and C.M. Rice Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277: Kurokohchi, K., K. Arima, and M. Nishioka A novel cytotoxic T-cell epitope presented by HLA-A24 molecule in hepatitis C virus infection. J Hepatol 34: Wertheimer, A.M., C. Miner, D.M. Lewinsohn, A.W. Sasaki, E. Kaufman, and H.R. Rosen Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 37: Cerny, A., P. Fowler, M.A. Brothers, M. Houghton, H.J. Schlicht, and F.V. Chisari Induction in vitro of a primary human antiviral cytotoxic T cell response. Eur J Immunol 25: Lauer, G.M., E. Barnes, M. Lucas, J. Timm, K. Ouchi, A.Y. Kim, C.L. Day, G.K. Robbins, D.R. Casson, M. Reiser, G. Dusheiko, T.M. Allen, R.T. Chung, B.D. Walker, and P. Klenerman High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 127: Cox, A.L., T. Mosbruger, Q. Mao, Z. Liu, X.H. Wang, H.C. Yang, J. Sidney, A. Sette, D. Pardoll, D.L. Thomas, and S.C. Ray Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 201:
4 8. Ito, A., T. Kanto, N. Kuzushita, T. Tatsumi, Y. Sugimoto, T. Miyagi, T. Takehara, K. Katayama, K. Mochizuki, N. Hiramatsu, A. Kasahara, I. Yoshiya, Y. Sasaki, M. Hori, and N. Hayashi Generation of hepatitis C virus-specific cytotoxic T lymphocytes from healthy individuals with peptide-pulsed dendritic cells. J Gastroenterol Hepatol 16: Dutoit, V., D. Ciuffreda, D. Comte, J.J. Gonvers, and G. Pantaleo Differences in HCVspecific T cell responses between chronic HCV infection and HIV/HCV co-infection. Eur J Immunol 35: Rosen, H.R., G. Marousek, and S. Chou A longitudinal analysis of T-cell epitope-coding regions of hepatitis C virus after liver transplantation. Transplantation 74: Hakamada, T., K. Funatsuki, H. Morita, T. Ugajin, I. Nakamura, H. Ishiko, Y. Matsuzaki, N. Tanaka, and M. Imawari Identification of novel hepatitis C virus-specific cytotoxic T lymphocyte epitopes by ELISpot assay using peptides with human leukocyte antigen-a*2402- binding motifs. J Gen Virol 85: Wong, D.K., D.D. Dudley, N.H. Afdhal, J. Dienstag, C.M. Rice, L. Wang, M. Houghton, B.D. Walker, and M.J. Koziel Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol 160: Cucchiarini, M., A.R. Kammer, B. Grabscheid, H.M. Diepolder, T.J. Gerlach, N. Gruner, T. Santantonio, J. Reichen, G.R. Pape, and A. Cerny Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cell Immunol 203: Kurokohchi, K., T. Akatsuka, C.D. Pendleton, A. Takamizawa, M. Nishioka, M. Battegay, S.M. Feinstone, and J.A. Berzofsky Use of recombinant protein to identify a motifnegative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region. J Virol 70:
5 15. Nakamoto, Y., S. Kaneko, H. Takizawa, Y. Kikumoto, M. Takano, Y. Himeda, and K. Kobayashi Analysis of the CD8-positive T cell response in Japanese patients with chronic hepatitis C using HLA-A*2402 peptide tetramers. J Med Virol 70: Guglietta, S., A.R. Garbuglia, V. Pacciani, C. Scotta, M.P. Perrone, L. Laurenti, E. Spada, A. Mele, M.R. Capobianchi, G. Taliani, A. Folgori, A. Vitelli, L. Ruggeri, A. Nicosia, E. Piccolella, and P. Del Porto Positive selection of cytotoxic T lymphocyte escape variants during acute hepatitis C virus infection. Eur J Immunol 35: Sidney, J., S. Southwood, V. Pasquetto, and A. Sette Simultaneous prediction of binding capacity for multiple molecules of the HLA B44 supertype. J Immunol 171: Timm, J., G.M. Lauer, D.G. Kavanagh, I. Sheridan, A.Y. Kim, M. Lucas, T. Pillay, K. Ouchi, L.L. Reyor, J. Schulze zur Wiesch, R.T. Gandhi, R.T. Chung, N. Bhardwaj, P. Klenerman, B.D. Walker, and T.M. Allen CD8 epitope escape and reversion in acute HCV infection. J Exp Med 200: Giuggio, V.M., H.L. Bonkovsky, J. Smith, and A.L. Rothman Inefficient recognition of autologous viral sequences by intrahepatic hepatitis C virus-specific cytotoxic T lymphocytes in chronically infected subjects. Virology 251: Ward, S., G. Lauer, R. Isba, B. Walker, and P. Klenerman Cellular immune responses against hepatitis C virus: the evidence base Clin Exp Immunol 128: Lauer, G.M., K. Ouchi, R.T. Chung, T.N. Nguyen, C.L. Day, D.R. Purkis, M. Reiser, A.Y. Kim, M. Lucas, P. Klenerman, and B.D. Walker Comprehensive analysis of CD8(+)-Tcell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 76: Kennedy, P.T., S. Urbani, R.A. Moses, B. Amadei, P. Fisicaro, J. Lloyd, M.K. Maini, G. Dusheiko, C. Ferrari, and A. Bertoletti The influence of T cell cross-reactivity on HCVpeptide specific human T cell response. Hepatology 43:
6 23. Schulze zur Wiesch, J., G.M. Lauer, C.L. Day, A.Y. Kim, K. Ouchi, J.E. Duncan, A.G. Wurcel, J. Timm, A.M. Jones, B. Mothe, T.M. Allen, B. McGovern, L. Lewis-Ximenez, J. Sidney, A. Sette, R.T. Chung, and B.D. Walker Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol 175:
Identification of Tick-Borne Encephalitis Virus CD4+ and CD8+ T-Cell Epitopes in Vaccinated or Naturally Infected Humans
Identification of Tick-Borne Encephalitis Virus CD4+ and CD8+ T-Cell Epitopes in Vaccinated or Naturally Infected Humans Schwaiger Julia Clinical Institute of Virology 29.06.2009 1 Thank you! Franz X.
A white paper for consideration by the NIAID Microbial Sequencing Program
Hepatitis C Virus Sequencing: Viral evolution, immune recognition and vaccine development. A white paper for consideration by the NIAID Microbial Sequencing Program Todd M. Allen, Ph.D. Assistant Professor
Hepatitis C Vaccines: Are we making progress?
Hepatitis C Vaccines: Are we making progress? Second International Hepatitis Cure and Eradication Meeting. Vancouver November, 2015 Objectives: Review the need for a preventive vaccine in 2015. Identify
Identification of T-cell epitopes of SARS-coronavirus for development of peptide-based vaccines and cellular immunity assessment methods
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES PKS Chan 陳 基 湘 S Ma 文 子 光 SM Ngai 倪 世 明 Key Messages 1. Subjects recovered from SARS-CoV infection retain memory of cellular immune response to epitopes
The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015
The role of IBV proteins in protection: cellular immune responses COST meeting WG2 + WG3 Budapest, Hungary, 2015 1 Presentation include: Laboratory results Literature summary Role of T cells in response
Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS
Prospects for Vaccines against Hepatitis C Viruses T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS HCV Vaccine Prevention strategies Protective immunity Barriers and solutions Vaccine candidates
International Journal of Integrative Biology A journal for biology beyond borders ISSN 0973-8363
Report International Journal of Integrative Biology A journal for biology beyond borders ISSN 0973-8363 In silico CD4+ T cell epitope mapping and HLA coverage analysis for proteins of human hepatitis E
Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection
Online Submissions: wjg.wjgnet.com World J Gastroenterol 2007 September 28; 13(36): 4839-4847 World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com 2007 WJG. All rights reserved. Robert Thimme,
6. JR Larrubia, MU Lokhande, S García-Garzón, J Miquel, A González-Praetorius, E Sanzde-Villalobos.
1. E. Moreno-Cubero, J Miquel, S García-Garzón, A. Lázaro, A González-Praetorius, C. Perna, E Sanz-de-Villalobos, JR Larrubia. Viral load decrease higher than 3log at week 12 of Peg.interferon alpha-2b/ribavirin
HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis
HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School
Hepatitis C Glossary of Terms
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
TRANSGENE SA, FRANCE 2. INSTITUT PASTEUR, FRANCE On behalf. AFEF 2013, Lille 02 nd October 2013
A MULTIVALENT ADENOVIRUS-BASED IMMUNOTHERAPEUTIC FOR TREATMENT OF CHRONIC HEPATITIS B INDUCES BROAD, ROBUST AND POLYFUNCTIONAL T CELLS IN NAIVE MICE AND EXERT AN EARLY ANTIVIRAL EFFECT IN HBV TOLERANT
New HLA class I epitopes defined by murine monoclonal antibodies
Human Immunology 71 (2010) 456 461 Contents lists available at ScienceDirect New HLA class I epitopes defined by murine monoclonal antibodies Nadim El-Awar a, *, Paul I. Terasaki b, Anh Nguyen a, Mamie
TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS
TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS Karine Lélu 1, Alexei Evlachev 1, Roland Kratzer 1, Sarah
Co-infected health-care workers
Co-infected health-care workers Y.Yazdanpanah Service Universitaire des Maladies Infectieuses et du Voyageur C.H. Tourcoing, Faculté de Médecine de Lille CNRS U362, Lille, France Co-infected health-care
The hepatitis B virus (HBV)
Cellular Immune Responses to the Hepatitis B Virus Polymerase 1,2 Eishiro Mizukoshi, 3 * John Sidney, Brian Livingston, Marc Ghany,* Jay H. Hoofnagle,* Alessandro Sette, and Barbara Rehermann 4 * CD4 T
CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma
CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma Occult HBV Infection: Assessment and Clinical Significance D. Lorne Tyrrell Director, Li Ka Shing Institute of Virology University of Alberta
Analysis of the adaptive immune response to West Nile virus
Analysis of the adaptive immune response to West Nile virus Jonathan Bramson (PI) Robin Parsons Alina Lelic Galina Denisova Lesley Latham Carole Evelegh Dmitri Denisov Strategy for characterizing T cell
Natalia Taborda Vanegas. Doc. Sci. Student Immunovirology Group Universidad de Antioquia
Pathogenesis of Dengue Natalia Taborda Vanegas Doc. Sci. Student Immunovirology Group Universidad de Antioquia Infection process Epidermis keratinocytes Dermis Archives of Medical Research 36 (2005) 425
specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins
Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes
There are about 170 million carriers of hepatitis C virus
Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model
Modelling and analysis of T-cell epitope screening data.
Modelling and analysis of T-cell epitope screening data. Tim Beißbarth 2, Jason A. Tye-Din 1, Gordon K. Smyth 1, Robert P. Anderson 1 and Terence P. Speed 1 1 WEHI, 1G Royal Parade, Parkville, VIC 3050,
Several human pathogens have the ability to suppress immune
Boosting immunity by antiviral drug therapy: A simple relationship among timing, efficacy, and success Natalia L. Komarova, Eleanor Barnes, Paul Klenerman, and Dominik Wodarz Institute for Advanced Study,
Treatment of Acute Hepatitis C
Management of Patients with Viral Hepatitis, Paris, 2004 Treatment of Acute Hepatitis C Michael P. Manns, Andrej Potthoff, Elmar Jaeckel, Heiner Wedemeyer Hepatitis C Virus (HCV) infection is a common
Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver
Boehringer Ingelheim- sponsored Satellite Symposium HCV Beyond the Liver HCV AS A METABOLIC MODIFIER: STEATOSIS AND INSULIN RESISTANCE Francesco Negro University Hospital of Geneva Switzerland Clinical
Assays to evaluate cell-mediated immunity. Guus Rimmelzwaan Department of Virology Erasmus Medical Center Rotterdam The Netherlands
Assays to evaluate cell-mediated immunity Guus Rimmelzwaan Department of Virology Erasmus Medical Center Rotterdam The Netherlands CBER/NIAID/WHO, Bethesda MD, December 11 2007 A working model of an antiviral
HIV/HCV Co-infection. HIV/HCV Co-infection. Epidemiology. Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London. Extrahepatic manifestations
HIV/HCV Co-infection Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London HIV/HCV Co-infection Epidemiology Impact of HIV on HCV Epidemiology Impact of HCV on HIV Management issues Future Extrahepatic
TOWARDS AN HIV VACCINE
why is it so hard to make an HIV vaccine and where are we now? Neal Nathanson, MD Emeritus Professor Department of Microbiology University of Pennsylvania School of Medicine 1 Estimated number of persons
UPDATE ON NEW HEPATITIS C MEDICINES
UPDATE ON NEW HEPATITIS C MEDICINES Diana Sylvestre, MD 2014 AASLD/IDSA Guidelines: Gt 1 Treatment naïve Interferon eligible: sofosuvir + ribavirin + PEG-IFN x 12 weeks Interferon ineligible: sofosbuvir
The challenge of developing a vaccine against hepatitis C virus
Journal of Hepatology 37 (2002) 684 695 Review The challenge of developing a vaccine against hepatitis C virus Xavier Forns 1, *, Jens Bukh 2, Robert H. Purcell 2 www.elsevier.com/locate/jhep 1 Liver Unit,
Human Leukocyte Antigens - HLA
Human Leukocyte Antigens - HLA Human Leukocyte Antigens (HLA) are cell surface proteins involved in immune function. HLA molecules present antigenic peptides to generate immune defense reactions. HLA-class
Case Finding for Hepatitis B and Hepatitis C
Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center
PEPVAC: a web server for multi-epitope vaccine development based on the prediction of supertypic MHC ligands
W138 W142 doi:10.1093/nar/gki357 PEPVAC: a web server for multi-epitope vaccine development based on the prediction of supertypic MHC ligands Pedro A. Reche 1,2, * and Ellis L. Reinherz 1,2 1 Laboratory
PEPVAC: A web server for multi-epitope vaccine development based on the prediction of supertypic
PEPVAC: A web server for multi-epitope vaccine development based on the prediction of supertypic MHC ligands Pedro A. Reche and Ellis L. Reinherz Laboratory of Immunobiology and Department of Medical Oncology,
Detection of T-cell T and their application to vaccine design
QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture Detection of T-cell T epitopes and their application to vaccine design EpiVax Inc. 16 Bassett Street Providence Rhode Island
Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas
Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Virus Shimizu et al., 1996 Positive single strand RNA virus Flaviviridae family, Hepacivirus genus 9.6 kbp genome ~3000
The Costimulatory Molecule CD27 Maintains Clonally
Immunity, Volume 35 Supplemental Information The Costimulatory Molecule CD7 Maintains Clonally Diverse CD8 + T Cell Responses of Low Antigen Affinity to Protect against Viral Variants Klaas P.J.M. van
T cell Epitope Prediction
Institute for Immunology and Informatics T cell Epitope Prediction EpiMatrix Eric Gustafson January 6, 2011 Overview Gathering raw data Popular sources Data Management Conservation Analysis Multiple Alignments
Medical publications on HBV and HCV Coinfection
Recent advances of HBV and HCV co-infection 台 中 榮 總 內 科 部 胃 腸 肝 膽 科 呂 宜 達 醫 師 2013.03.28 Outline Epidemiology of HBV and HCV coinfection Clinical significance of HBV and HCV coinfection Interplay between
Positive impact of HCV treatment initiation on health outcomes in injecting drug users
Positive impact of HCV treatment initiation on health outcomes in injecting drug users Perrine ROUX, PhD Substance Use Research Center, Columbia University, NY Inserm U912, SE4S, Marseille Introduction
Hepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS
Hepatitis B and C Co-infection Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Objectives Review natural history of hepatitis coinfection Brief overview of treatment indications for
III III a IIOI OlD III OlD IIO 1101 010 III DID III 100 III0 II uii IIi
III III a IIOI OlD III OlD IIO 1101 010 III DID III 100 III0 II uii IIi US oi ^^_._.,o.i ^,) United States (12) Patent Application Publication Buyse et al. (43) Pub. Date: Oct. 28, (54) HPV POLYEPITOPE
Acute viral hepatitis B (AVH-B) is successfully. A Randomized Controlled Trial of Lamivudine to Treat Acute Hepatitis B. Patients and Methods
A Randomized Controlled Trial of Lamivudine to Treat Acute Hepatitis B M. Kumar, S. Satapathy, R. Monga, K. Das, S. Hissar, C. Pande, B. C. Sharma, and S. K. Sarin The role of antivirals in patients with
Early HIV- specific CD8 + T cell responses in treated and untreated hyper acute HIV infec=on in the FRESH cohort
Early HIV- specific CD8 + T cell responses in treated and untreated hyper acute HIV infec=on in the FRESH cohort Zaza M&ne Ndhlovu, PhD Instructor in Medicine Ragon Ins&tute of MGH, MIT and Harvard Senior
Hapten - a small molecule that is antigenic but not (by itself) immunogenic.
Chapter 3. Antigens Terminology: Antigen: Substances that can be recognized by the surface antibody (B cells) or by the TCR (T cells) when associated with MHC molecules Immunogenicity VS Antigenicity:
Molecular Diagnosis of Hepatitis B and Hepatitis D infections
Molecular Diagnosis of Hepatitis B and Hepatitis D infections Acute infection Detection of HBsAg in serum is a fundamental diagnostic marker of HBV infection HBsAg shows a strong correlation with HBV replication
Hepatitis C: Epidemiology, Transmission, and Screening. Jennifer Price, MD Assistant Professor of Medicine University of California San Francisco
Activity Code FA376 Hepatitis C: Epidemiology, Transmission, and Screening Jennifer Price, MD Assistant Professor of Medicine University of California San Francisco Learning Objectives Upon completion
THE INFLUENCE OF TISSUE (IN)COMPATIBILITY IN UMBILICAL CORD BLOOD TRANSPLANTATION
THE INFLUENCE OF TISSUE (IN)COMPATIBILITY IN UMBILICAL CORD BLOOD TRANSPLANTATION Matjaž Jeras Blood Transfusion Centre of Slovenia Tissue Typing Center Šlajmerjeva 6, 1000 Ljubljana, Slovenia matjaz.jeras@ztm.si
Title: Mapping T cell epitopes in PCV2 capsid protein - NPB #08-159. Date Submitted: 12-11-09
Title: Mapping T cell epitopes in PCV2 capsid protein - NPB #08-159 Investigator: Institution: Carol Wyatt Kansas State University Date Submitted: 12-11-09 Industry summary: Effective circovirus vaccines
Mid-Clinical Stage Antiviral Drug Development Company
BIOTRON LIMITED (ASX:BIT) Mid-Clinical Stage Antiviral Drug Development Company Investor Update 20 August 2015 Dr Michelle Miller Managing Director +61 412 313329 mmiller@biotron.com.au www.biotron.com.au
HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
BioMmune Technologies Inc. Corporate Presentation 2015
BioMmune Technologies Inc Corporate Presentation 2015 * Harnessing the body s own immune system to fight cancer & other autoimmune diseases BioMmune Technologies Inc. (IMU) ABOUT A public biopharmaceutical
Hing wars. During World War II, there was a series of hepatitis outbreaks
Hepatitis C: Toward a Cure and Eradication 1 CHARLES M. RICE Head, Laboratory of Virology and Infectious Disease Scientific and Executive Director Center for the Study of Hepatitis C Rockefeller University
T-cell epitope mapping of ORF2 and ORF3 proteins of human hepatitis E virus
Journal of Viral Hepatitis, 7,, 9 doi:./j.5-9..79.x T-cell epitope mapping of ORF and ORF proteins of human hepatitis E virus R. Aggarwal, R. Shukla, S. Jameel, S. Agrawal, P. Puri, V. K. Gupta, A. P.
The immunogenicity of the Hepatitis C virus (HCV) non- structural protein 3 (NS3) was investigated using different
Different Hepatitis C Virus Nonstructural Protein 3 (Ns3)-DNA Expressing Vaccines Induce in HLA-A2.1 Transgenic Mice Stable Cytotoxic T Lymphocytes That Target One Major Epitope CARINE BRINSTER, 1 STÉPHANIE
New developments in antigen-specific immunotherapies Novel therapeutic vaccines offer hope in the fight against chronic infectious disease and cancer
New developments in antigen-specific immunotherapies Novel therapeutic vaccines offer hope in the fight against chronic infectious disease and cancer Vaccination has been used effectively for more than
Final Review. Aptamers. Making Aptamers: SELEX 6/3/2011. sirna and mirna. Central Dogma. RNAi: A translation regulation mechanism.
Central Dogma Final Review Section Week 10 DNA RNA Protein DNA DNA replication DNA RNA transcription RNA Protein translation **RNA DNA reverse transcription http://bass.bio.uci.edu/~hudel/bs99a/lecture20/lecture1_1.html
Chapter 43: The Immune System
Name Period Our students consider this chapter to be a particularly challenging and important one. Expect to work your way slowly through the first three concepts. Take particular care with Concepts 43.2
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova HBV ed HCV Due virus Diversi ma con molte Cose in Comune
AAB 2013 Annual Meeting & Educational Conference
American Association of Bioanalysts AAB 2013 Annual Meeting & Educational Conference Occult Hepatitis and HIV Prophylaxis Thursday, May 16, 2013, 9:45 a.m. John H. Hughes, Ph.D. Dept Molecular Virology,
Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years
Claim#:021914-174 Initials: J.T. Last4SSN: 6996 DOB: 5/3/1970 Crime Date: 4/30/2013 Status: Claim is currently under review. Decision expected within 7 days Claim#:041715-334 Initials: M.S. Last4SSN: 2957
Cancer Vaccines and the Importance of Overcoming Immunological T-Cell Response
Chapter 2 / The Rational Design of T-Cell Epitopes 11 2 The Rational Design of T-Cell Epitopes With Enhanced Immunogenicity John Fikes, PhD CONTENTS THE CHALLENGE OF OVERCOMING IMMUNOLOGICAL TOLERANCE
CHARACTERISTICS OF CHRONIC HEPATITIS C AMONG INTRAVENOUS DRUG USERS: A COMPARATIVE ANALYSIS
& CHARACTERISTICS OF CHRONIC HEATITIS C AMONG INTRAVENOUS DRUG USERS: A COMARATIVE ANALYSIS Maja Jovanović 1, Branislav Jovanović 1, Milena otić2 *, Ljiljana Konstantinović 1, Miodrag Vrbić 1, Biljana
Interleukin-10 gene promoter polymorphism and risk of liver cirrhosis
Interleukin-10 gene promoter polymorphism and risk of liver cirrhosis Y. Liu 1, M.C. Yu 2, A.Q. Zhang 1, Y.B. Wang 1, K. Jiang 1 and J.H. Dong 1 1 Department of Hepatobiliary Surgery, Chinese PLA General
Identification of CD8 + T Cell Epitopes in the West Nile Virus Polyprotein by Reverse-Immunology Using NetCTL
Identification of CD8 + T Cell Epitopes in the West Nile Virus Polyprotein by Reverse-Immunology Using NetCTL Mette Voldby Larsen 1 *, Alina Lelic 2, Robin Parsons 2, Morten Nielsen 1, Ilka Hoof 1, Kasper
Epidemiology of Hepatitis C Infection. Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid
Epidemiology of Hepatitis C Infection Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid Worldwide Prevalence of Hepatitis C 10% No data available WHO.
Immune Epitope Database NEWSLETTER Volume 7, Issue 1 http://www.iedb.org March 2010
Immune Epitope Database NEWSLETTER Volume 7, Issue 1 http://www.iedb.org March 2010 IEBD 2.3 Released January 19 The latest version of the IEDB website was released on January 19. A list of the new features
Vaccine Development for Hepatitis C: Lessons from the Past Turn into Promise for the Future
Vaccine development for hepatitis C REVIEW ARTICLE Vaccine Development for Hepatitis C: Lessons from the Past Turn into Promise for the Future Chi-Tan Hu Division of Gastroenterology, Department of Internal
Cytoreductive Therapy for Autologous Cell Therapy in HIV
Cytoreductive Therapy for Autologous Cell Therapy in HIV Ronald Mitsuyasu, MD Professor of Medicine UCLA Center for Clinical AIDS Research and Education (CARE Center) HSC Transfer from CCR5-delta 32 Donor
In this study, the DCV+ASV regimen had low rates of discontinuation (5%) due to adverse events, and low rates of serious adverse events (5.
BMS Submits First All-Oral, Interferon-Free and Ribavirin-Free Treatment Regimen for Regulatory Review in Japan for Patients with Chronic Hepatitis C Infection An overall SVR 24 rate of 84.7 percent was
Downloaded from: http://researchonline.lshtm.ac.uk/19718/
Dockrell, H M; Brahmbhatt, S; Robertson, B D; Britton, S; Fruth, U; Gebre, N; Hunegnaw, M; Hussain, R; Manadhar, R; Murrillo, L; Pessolani, M C; Roche, P; Salgado, J L; Sampaio, E; Shahid, F; Thole, J
G V Papatheodoridis, S G R G Barton, D Andrew, G Clewley, S Davies, A P Dhillon, G Dusheiko, B Davidson, K Rolles, A K Burroughs
Gut 1999;45:427 434 427 Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of diverent immunosuppressive
CD8+ T Cell Response to Interruptible Chronic HCV Infection
Analysis of the CD8+ T cell response against hepatitis C virus in intravenous drug users Inaugural-Dissertation zur Erlangung des Doktorgrades Dr. rer. nat. der Fakultät für Biologie an der Universität
Hepatitis C Virus Infection in Massachusetts: A tale of two epidemics
Hepatitis C Virus Infection in Massachusetts: A tale of two epidemics Daniel Church, MPH Massachusetts Department of Public Health Bureau of Infectious Disease 1 Goals of presentation Provide an overview
HBV DNA < monitoring interferon Rx
Hepatitis B Virus Suspected acute hepatitis >>Order: Acute Unknown hepatitis screen Suspected chronic hepatitis >>Order: Chronic unknown hepatitis screen Acute HBV or Delayed Anti HBs response after acute
Prediction of T cell epitopes for the utility of vaccine development from structural proteins of dengue virus variants using in silico methods
Indian Journal of Biotechnology Vol 8, April 2009, pp 193-198 Prediction of T cell epitopes for the utility of vaccine development from structural proteins of dengue virus variants using in silico methods
Identification of Conserved and HLA Promiscuous DENV3 T-Cell Epitopes
Identification of Conserved and HLA Promiscuous DENV3 T-Cell Epitopes Eduardo J. M. Nascimento 1,2 *, Robbie B. Mailliard 1, Asif M. Khan 3,4, John Sidney 5, Alessandro Sette 5, Nicole Guzman 6, Michael
João Silva de Mendonça, MD, PhD Infectious Diseases Service Hospital do Servidor Público Estadual São Paulo - Brazil
Brazilian Ministry of Health, Brazilian Society of Hepatology PAHO, Viral Hepatitis Prevention Board PART III SESSION 9 Prevention and control of Viral Hepatitis in Brazil HEPATITIS IN SPECIAL RISK GROUPS/
HCV: Diagnostic Testing and Staging. HCV: Diagnostic Tests
HCV: Diagnostic Testing and Staging HCV: Diagnostic Tests Necessary HCV Antibody HCV-RNA Genotype Not Necessary ALT IL28 B 1 ALT as a Sole Trigger for Screening Misses Some Infected Patients Patients*
DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME
DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME Johan Neyts Rega Institute for Medical Research, University of Leuven, Belgium Johan.neyts@rega.kuleuven.be www.antivirals.be Pentalfa, 28
The immunogenic vaccine against HCV and HBV
National Centre for Research and Development, The immunogenic vaccine against HCV and HBV Katarzyna Grzyb Laboratory of Virus Molecular Biology Intercollegate Faculty of Biotechnology UG-MUG 1 Hepatitis
The Natural History of Chronic Hepatitis B Virus Infection
The Natural History of Chronic Hepatitis B Virus Infection Brian J. McMahon, M.D. 1 ABSTRACT Three stages of chronic hepatitis B virus (HBV) infection are recognized: the immune tolerant phase, the chronic
The natural history of chronic HBV infection
Hepatitis B Viral Factors in HBeAg-Negative Carriers with Persistently Normal Serum Alanine Aminotransferase Levels Chih-Lin Lin, 1* Li-Ying Liao, 1* Chun-Jen Liu, 2 Ming-Whei Yu, 3 Pei-Jer Chen, 2,4 Ming-Yang
Global Under Diagnosis of Viral Hepatitis
Global Under Diagnosis of Viral Hepatitis Mel Krajden MD, FRCPC Medical Head, Hepatitis Clinical Prevention Services Associate Medical Director, Public Health Microbiology & Reference Laboratory BC Centre
Guidance for Industry Antiviral Product Development Conducting and Submitting Virology Studies to the Agency
Guidance for Industry Antiviral Product Development Conducting and Submitting Virology Studies to the Agency U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
The autophagy machinery is required to initiate hepatitis C virus infection. Marlène Dreux
The autophagy machinery is required to initiate hepatitis C virus infection Marlène Dreux Hepatitis C virus life cycle HCV particles internalization RNA replication RNA translation ER HCV assembly and
Optimising therapy in chronic hepatitis B: Switch or add treatment
Optimising therapy in chronic hepatitis B: Switch or add treatment Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University,Thailand NA + NA Percent with resistance
Fat and Viral Liver Disease
Fat and Viral Liver Disease Francesco Negro Viropathology Unit University of Geneva Medical Center Geneva, Switzerland Mainz, September 20, 2008 Steatosis and HBV Steatosis in HBV infection: prevalence
HLA Class I-Restricted Cytotoxic T-Cell Epitopes of the Respiratory Syncytial Virus Fusion Protein
JOURNAL OF VIROLOGY, Nov. 2000, p. 10240 10244 Vol. 74, No. 21 0022-538X/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. HLA Class I-Restricted Cytotoxic T-Cell Epitopes
BACKGROUND MEDIA INFORMATION Fast facts about liver disease
BACKGROUND MEDIA INFORMATION Fast facts about liver disease Liver, or hepatic, disease comprises a wide range of complex conditions that affect the liver. Liver diseases are extremely costly in terms of
LIAISON XL HCV Ab Accurate diagnosis of the early stage of HCV infection
Hepatitis and Retrovirus LIAISON XL HCV Ab Accurate diagnosis of the early stage of HCV infection FOR OUTSIDE THE US AND CANADA ONLY LIAISON XL HCV Ab is Your solution LIAISON XL murex HCV Ab main features
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
HEPATITIS COINFECTIONS
HEPATITIS COINFECTIONS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures (Activity w/i 12 months)
2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line
i 1 INTRODUCTION 1.1 Human Hepatitis B virus (HBV) 1 1.1.1 Pathogenesis of Hepatitis B 1 1.1.2 Genome organization of HBV 3 1.1.3 Structure of HBV virion 5 1.1.4 HBV life cycle 5 1.1.5 Experimental models
Liver Disease and Therapy of Hepatitis B Virus Infections
Liver Disease and Therapy of Hepatitis B Virus Infections University of Adelaide Catherine Scougall Arend Grosse Huey-Chi Low Allison Jilbert Fox Chase Cancer Center Chunxiao Xu Carol Aldrich Sam Litwin
Clinical Application of HBs quantification
Clinical Application of HBs quantification Hepatology on the Nile 2 Advances in Liver Disease 2014, "World Expert Review» Wednesday, September 24, 2014 Pr Tarik Asselah MD, PhD; Service d Hépatologie &
Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL
Hepatitis C Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Recent Advances in Hepatitis C Appreciation that many patients are undiagnosed Improved screening to identify infected persons Assessment
DNA Vaccine for Chronic Hepatitis C
Novel Vaccine Development (3:00PM~3:30PM) DNA Vaccine for Chronic Hepatitis C : Preclinical Evaluation of Immunogenicity and Safety of VGX-6150 Moonsup JEONG, Ph.D. Director of Pharma R&D Division GeneOne
3/25/2014. April 3, 2014. Dennison MM, et al. Ann Intern Med. 2014;160:293 300.
April 3, 2014 3.6 million persons ever infected; 2.7 million chronic infections 1 Up to 75% unaware of status Transmitted through percutaneous exposure to infected blood Injection drug use (IDU) is the